Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accumulated Expenses (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Accumulated Expenses data on record, last reported at $47.0 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 38.97% year-over-year to $47.0 million; the TTM value through Dec 2025 reached $47.0 million, up 38.97%, while the annual FY2025 figure was $47.0 million, 38.97% up from the prior year.
  • Accumulated Expenses reached $47.0 million in Q4 2025 per CLDX's latest filing, up from $39.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $47.0 million in Q4 2025 and bottomed at $7.0 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $18.9 million, with a median of $15.2 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: dropped 5.8% in 2021, then skyrocketed 87.07% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $8.0 million in 2021, then surged by 61.08% to $12.8 million in 2022, then surged by 71.63% to $22.0 million in 2023, then soared by 53.62% to $33.8 million in 2024, then surged by 38.97% to $47.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $47.0 million in Q4 2025, $39.7 million in Q3 2025, and $28.4 million in Q2 2025.